title: Discontinued drugs in 2008: endocrine and metabolic.
abstract: This perspective summarizes key compounds from the endocrine and metabolic area that were discontinued during the calendar year 2008. This is a continuation in a series of perspectives of each of the editorial areas summarized by Expert Opinion on Investigational Drugs. The candidates covered in this summary were being developed for the treatment of diabetes, diabetic complications, anti-atherosclerosis and obesity.
authors.affiliation: Metabolic Diseases Development Company, 125 S Kalamazoo Mall #202, Kalamazoo, MI 49007, USA. JColca@msdex.com
authors.forename: Jerry R
authors.initials: JR
authors.lastname: Colca
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D004700:Endocrine System Diseases / Q000188:drug therapy*; D006801:Humans; D008659:Metabolic Diseases / Q000188:drug therapy*; D017211:Treatment Failure
chemical_list: D015507:Drugs, Investigational